A Phase 1b, Open-label, Multi-center, Single Arm, Dose Finding Study to Assess Safety and Pharmacokinetics of the Oral Combination of Panobinostat and Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera-myelofibrosis (PPV-MF) or Post-essential Thrombocythemia-myelofibrosis (PET-MF)

Trial Profile

A Phase 1b, Open-label, Multi-center, Single Arm, Dose Finding Study to Assess Safety and Pharmacokinetics of the Oral Combination of Panobinostat and Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera-myelofibrosis (PPV-MF) or Post-essential Thrombocythemia-myelofibrosis (PET-MF)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Panobinostat (Primary) ; Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 13 Feb 2017 Planned End Date changed from 1 Dec 2016 to 13 Dec 2017.
    • 13 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 13 Dec 2017.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top